JP2024516828A - がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤 - Google Patents

がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤 Download PDF

Info

Publication number
JP2024516828A
JP2024516828A JP2023566518A JP2023566518A JP2024516828A JP 2024516828 A JP2024516828 A JP 2024516828A JP 2023566518 A JP2023566518 A JP 2023566518A JP 2023566518 A JP2023566518 A JP 2023566518A JP 2024516828 A JP2024516828 A JP 2024516828A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
independently
alkyl
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516828A5 (https=
Inventor
リンゲマン，ロバート
マルカス，リンダ・エイチ
ヒッキー，ロバート・ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2024516828A publication Critical patent/JP2024516828A/ja
Publication of JP2024516828A5 publication Critical patent/JP2024516828A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023566518A 2021-04-30 2022-04-29 がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤 Pending JP2024516828A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182408P 2021-04-30 2021-04-30
US63/182,408 2021-04-30
PCT/US2022/026928 WO2022232509A1 (en) 2021-04-30 2022-04-29 Pcna inhibitors and egfr inhibitors for cancer treatment

Publications (2)

Publication Number Publication Date
JP2024516828A true JP2024516828A (ja) 2024-04-17
JP2024516828A5 JP2024516828A5 (https=) 2025-05-02

Family

ID=83847341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566518A Pending JP2024516828A (ja) 2021-04-30 2022-04-29 がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤

Country Status (11)

Country Link
US (1) US20240245634A1 (https=)
EP (1) EP4330224A4 (https=)
JP (1) JP2024516828A (https=)
KR (1) KR20240004548A (https=)
CN (1) CN117460714A (https=)
AU (1) AU2022264802A1 (https=)
BR (1) BR112023022530A2 (https=)
CA (1) CA3217330A1 (https=)
IL (1) IL307281A (https=)
MX (1) MX2023012744A (https=)
WO (1) WO2022232509A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途
CN118546074B (zh) * 2024-05-27 2025-06-06 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348512B (zh) * 2015-09-17 2021-09-03 希望之城 Pcna抑制剂
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法

Also Published As

Publication number Publication date
CA3217330A1 (en) 2022-11-03
CN117460714A (zh) 2024-01-26
AU2022264802A1 (en) 2023-10-12
EP4330224A4 (en) 2025-03-19
WO2022232509A1 (en) 2022-11-03
EP4330224A1 (en) 2024-03-06
MX2023012744A (es) 2024-01-05
IL307281A (en) 2023-11-01
US20240245634A1 (en) 2024-07-25
BR112023022530A2 (pt) 2024-01-16
KR20240004548A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP7690553B2 (ja) Ｐｃｎａ阻害剤
TWI784255B (zh) 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
JP2024516828A (ja) がん治療のためのｐｃｎａ阻害剤及びｅｇｆｒ阻害剤
CN114599361A (zh) Prmt5抑制剂的药物组合物
CN107873032A (zh) 苯并氧氮杂*噁唑烷酮化合物及其使用方法
AU2022216284A9 (en) Combination therapy for treating abnormal cell growth
JP6933644B2 (ja) アンドロゲン受容体拮抗薬
JP2020523348A (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
KR20240144090A (ko) Ptpn11 억제제 및 kras g12c 억제제를 사용한 조합 요법
CN115381832A (zh) 癌症的治疗
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
EA052352B1 (ru) Ингибиторы pcna и ингибиторы egfr для лечения рака
CN108348519A (zh) 经氯苯取代的氮杂芳基化合物
HK40083903A (en) Treatment of cancer
WO2017205611A1 (en) Estrogen receptor modulator combinations
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
HK40042521B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
HK40039385B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
WO2018237190A1 (en) Pyridopyrazine compounds and uses thereof
HK40001545A (en) Treatment of cancer
BR112018005331B1 (pt) Inibidores de pcna
HK1258793B (en) Pcna inhibitors
HK1253003B (zh) 苯并氧氮杂䓬恶唑烷酮化合物及其使用方法
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250423